Connor Clark & Lunn Investment Management Ltd. reduced its position in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 38.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,109 shares of the company's stock after selling 18,615 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in HUTCHMED were worth $434,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Point72 Hong Kong Ltd purchased a new position in shares of HUTCHMED during the third quarter worth about $421,000. State Street Corp lifted its position in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after acquiring an additional 3,078 shares during the period. Jane Street Group LLC grew its stake in shares of HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after purchasing an additional 49,366 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED in the third quarter valued at approximately $35,000. Finally, Crossmark Global Holdings Inc. raised its stake in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after purchasing an additional 1,799 shares during the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.
Get Our Latest Analysis on HUTCHMED
HUTCHMED Stock Down 2.7 %
NASDAQ HCM traded down $0.40 during trading hours on Wednesday, hitting $14.22. 85,000 shares of the stock were exchanged, compared to its average volume of 105,967. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a 12-month low of $12.84 and a 12-month high of $21.92. The stock has a 50-day moving average of $14.69 and a 200 day moving average of $16.46.
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
